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ABSTRACT

BACKGROUND: Chronic inflammation has been implicated in the pathogenesis of
many chronic diseases, including colorectal cancer. Obesity has been identified as a risk
factor for colorectal cancer via induction of a chronic state of low-grade bowel
inflammation due to excessive release of inflammatory cytokines such as C-Reactive
protein (CRP) by adipocytes. Prior studies have produced evidence of positive
associations between CRP and colon cancer risk but none to date have assessed if
elevated CRP is an independent risk factor when controlling for obesity. Also,
controversy exists about which measure of adiposity best predicts risk of colon cancer.
METHODS: We examined these questions using the National Health and Nutrition
Examination Survey III (NHANES III) database linked to the National Death Index. In
addition to CRP level, we studied the following four adiposity measures: body mass
index, waist circumference, waist-to-hip ratio, and a new index developed by the NIH
that stratifies BMI according to waist circumference. Outcome variables were: all-cause,
colorectal cancer, other obesity related cancers, and all other causes. Dichotomous and
Polytomous Logistic Regression were performed. RESULTS: CRP levels showed
positive but weak correlations with adiposity measures. In the age-adjusted and
multivariate Dichotomous Logistic Regression analyses, elevated CRP level was
significantly associated with all-cause mortality (OR=1.63 95% CI 1.40-1.91; and
OR=1.32, 95% CI 1.08-1.61; respectively.) Using age-adjusted and multivariate
Polytomous Logistic Regression, elevated CRP level was associated with mortality from
colorectal cancer (OR=2.72, 95% CI 1.30-5.72; OR= 2.44, 95% CI 1.20-4.94;
respectively.) OR estimates did not change appreciably when adiposity measures were
included in multivariate models. Further, none of the body measures of adiposity were
significantly associated with cause-specific death in either age-adjusted or multivariate
analyses. CONCLUSIONS: Our findings suggest that CRP may be an independent risk
factor for all-cause and, more so, for colorectal cancer mortality. We speculate that the
surprising effects related to body measures of adiposity may reflect misclassification
related to the single baseline obesity measurement, taken during 1988-94, in light of the
obesity epidemic that emerged during the follow-up time period. Further investigation of
this relationship is warranted to determine of elevated CRP remains an independent risk
factor when longitudinal adiposity history is known.

i

1.0 INTRODUCTION

1.1 Cancer
Cancer is a group of diseases characterized by uncontrollable cell growth and spread of
abnormal cells (ACS, 2008.) Cancer is the second most common cause of death in the
United States, accounting for 1 out of every 4 deaths (ACS, 2008.) 1,437,180 new
cancer cases were diagnosed in the United States and 565,650 Americans died from
cancer in 2008 alone (ACS, 2008.) The impact of cancer on society is seen not only in
the rates of morbidity and mortality of Americans but also in terms of economic
consequences as well. The National Institutes of Health estimates that the overall cost of
cancer in 2007 was $219 billion dollars, with $89.0 billion used for direct medical costs,
$18.2 billion from indirect morbidity costs, and $112.0 billion from indirect mortality
costs (ACS, 2008.) To help relieve the heavy burden, the U.S. Department of Health
and Human Services identified cancer as a primary focus area for research and programs
to improve health in the country (DHHS, 2000.)
Overall cancer incidence and death rates have decreased steadily in the United
States over the past few decades due to better screening techniques and advances in
treatment methodologies. Yet, it may be possible to prevent or delay certain cancers as
it has been estimated that two-thirds of cancers are caused by modifiable risk factors
such as tobacco use, alcohol use, overweight, physical inactivity, and unprotected
exposure to ultraviolet rays (ACS, 2008.) Furthermore, overall rates of cancer are
expected to rise as the population ages. Also, there is some speculation that as more
1

people adopt habits and lifestyles which confer greater risk, cancer is expected to
overtake cardiovascular disease as the leading cause of death worldwide by 2010 (IARC,
2008.) Hence, it is important that research on the modifiable risk factors and underlying
mechanisms of cancer be advanced so that health professionals can develop effective
practices to prevent and treat cancer.

1.2 Inflammation and Cancer
An emerging theory linking behavioral risk factors with cancer development postulates
that chronic, systemic inflammation contributes to the carcinogenic process by
promoting cellular injury and proliferation, processes that can produce a favorable
environment for genetic mutations to occur (Helzlsouer et al., 2006.) The link between
cancer and inflammation was first postulated in 1863 by Virchow who speculated that
the origin of cancer was at sites of chronic inflammation (Hong et al., 2007.) Studies of
chronic inflammation and cancer have provided promising evidence that individuals
with inflammatory diseases are at greater risk for developing certain types of cancer
specific to the site of inflammation, such as colorectal cancer among those with irritable
bowel diseases, liver cancer among chronic Hepatitis C sufferers, and stomach cancer
among those with chronic ulcers (Bernstein, 2006; Sherman, 2006; Schottenfeld et al.,
2006.) Recent studies have shown that inflammatory proteins may induce repeated local
cellular injury through oxidative damage which, in turn, may result in genetic mutations
or disruption of the formation of proteins involved in DNA repair and apoptosis (Lu et
al., 2006; Peisajovich et al, 2008; Heikkila et al., 2009.) These findings suggest that
chronic inflammation may play a causal role in malignancy as well as in progression.
2

A number of markers have been identified as useful tools to measure chronic
systemic inflammation. C-Reactive Protein (CRP), an acute-phase reactant produced by
the liver and adipocytes, has emerged as a reliable, non-specific serologic marker of
inflammation (Helzlsouer et al., 2006.)

CRP is an innate opsonin, a protein that

recognizes microbes and other potentially harmful matter inside the body and promotes
their uptake and destruction by immune cells (Peisajovich et al., 2008.) CRP levels in
the body may rise in response to many factors, including the presence of acute
conditions such as burns and heart attacks or chronic conditions such as arthritis and
diabetes. There is also evidence of variation in CRP level due to polymorphisms in
genes that code for CRP production (Black et al., 2004; Heikkila et al., 2009.) The
association of elevated CRP levels with outcomes such as cardiovascular disease, type II
diabetes, and, most recently, certain types of cancer, has created growing interest in
ascertaining how inflammation might contribute to etiology (Danesh et al., 2004;
Peisajovich et al., 2008; Heikkila et al., 2009; Grootendorst et al., 2007.)
Several different theories have been proposed to explain why high CRP levels
are associated with increased risk for cancer incidence.

First, CRP could become

elevated when the tissue surrounding a growing tumor becomes inflamed due to
infringement upon the organ (Peisajovich et al., 2008.) Second, CRP elevation could be
related to immune system response to tumor antigens which may be reflected by
elevated systemic inflammation (Balkwill et al., 2001.) Another theory is that the
production of inflammatory mediators such as prostaglandins or COX-2 by cancer cells
may stimulate CRP production (Heikkila et al., 2007.) Lastly, a rise in CRP also could
be a response to pre-malignant lesions (Peisajovich et al., 2008.)

The temporal
3

significance of elevated markers of systemic inflammation has yet to be determined. A
number of prospective studies, however, collected baseline measurements of CRP
several years before the diagnosis of cancer and have provided evidence that CRP levels
were elevated before any measurable signs of cancer were detected (Helzlsouer et al.,
2006; Tsilidis et al., 2008.) This finding suggests that CRP may be useful as a marker to
identify individuals at risk for cancer.
In addition, it has been postulated that C-reactive protein may have prognostic
value as an indicator of mortality risk. Several studies have demonstrated an association
between elevated CRP and risk of overall mortality as well as cause-specific death from
cardiovascular disease and cancer (Suleiman et al., 2006; Cae et al., 2007.) In a cohort
study conducted by Marsik et al. (2008) of almost 275,000 individuals, a 3.3 fold risk for
all-cause death was found in individuals with the highest levels of CRP compared with
individuals with the lowest level of CRP; a similar yet attenuated risk was noted for
individuals with moderate levels of CRP compared to individuals with low CRP,
indicating a dose-response relationship.
The link between CRP and mortality has been seen in both short-term and longterm prospective studies. A study by Makita et al. (2008) following patients for a mean
of only 2.7 years found an odds ratio of 2.26 for overall mortality among individuals
with CRP levels greater than 1 mg/L. Koenig et al. (2008) found significant associations
between CRP levels greater than 3 mg/L and overall mortality (OR=1.88),
cardiovascular disease mortality (OR=2.15) and cancer mortality (OR=1.74) for
individuals with a mean follow-up time of 7.1 years. Therefore, CRP shows promise as
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a potential marker for predicting negative health outcomes in both short- and long-term
prospective studies.

1.3

Colorectal Cancer Burden

Colorectal cancer (CRC) is the third most common cancer in the United States, with
108,070 colon cancers and 40,740 rectal cancers documented in 2008 (ACS, 2008.) An
estimated 49,960 deaths among males and females resulted from colorectal cancer in
2008, making it the second most lethal cancer in the United States following lung cancer
(ACS, 2008.) Colorectal cancer incidence and death has decreased during the last two
decades, primarily due to better detection at early stages from increases in colonoscopy
screening and improved treatment modalities. A sharp increase in colorectal cancer,
however, has been observed in rapidly developing countries and among migrant
populations in the U.S., consistent with long-standing evidence that environmental and
lifestyle factors to play a key role in colorectal carcinogenesis (Whittemore et al., 1990;
IARC, 2008.)

1.4 Behavioral Risk Factors and Mortality from Colorectal Cancer
Several factors may increase the risk of developing and dying from colorectal cancer.
Age is the most prominent risk factor for colorectal cancer, with over 90% of cases
being diagnosed in people 50 years and older (ACS, 2008.) Familial or personal history
of colorectal cancer, polyps, or inherited genetic syndromes such as familial
adenomatous polyposis or hereditary non-polyposis colorectal cancer may also be strong
indicators of risk. Personal history of chronic inflammatory bowel diseases such as
5

Irritable Bowel Syndrome and Crohns Disease also confers risk for colorectal cancer by
increasing gut permeability to allow greater exposure of colonocytes to luminal antigens
(Soderholm et al., 2004.)
From a population-based perspective, the majority of risk for colon cancer,
however, has been attributed to modifiable risk factors such as obesity, physical
inactivity, smoking, heavy alcohol consumption, a diet high in red meat and processed
foods, and inadequate dietary fiber intake (Chao et al., 2005; Park et al., 2005; Frezza et
al., 2006; ACS, 2008.) These preventable risk factors play significant roles in the
etiology of colorectal cancer, and it is projected that colorectal cancer rates will rise as
the world realizes the consequences borne of the “Westernized” trend in globalization,
which to date has been associated with concomitant increases in obesity and physical
inactivity.

1.5 Adiposity and Colorectal Cancer
As mentioned, a key risk factor for colorectal cancer is obesity. A significant dilemma
traditionally encountered in most studies of obesity and health outcomes is deciding
which body measurement of adiposity best reflects risk of disease. Dozens of studies
have evaluated the relationship of various adiposity measures (i.e. body mass index,
waist circumference, waist-to-hip ratio), finding a moderate positive relationship
between increasing obesity and increasing risk of CRC incidence and mortality (Russo et
al., 1998; Moore et al., 2004; MacInnis et al., 2006; Pischon et al., 2006; Larsson et al.,
2007; Wang et al., 2008.) Odds ratios for obesity and development of or death from
colorectal cancer ranged from 1.07 to 1.79, depending on the adiposity measure used
6

and the population under study (Larsson et al., 2007; Moghaddam et al., 2007; Wang et
al., 2008.) Crude body weight and body mass index were more strongly related to CRC
incidence and death in men than in women, while waist circumference and waist-to-hip
ratio were more strongly correlated with CRC incidence and death among women than
among men (Russo et al., 1998; Pischon et al., 2006; Larsson et al., 2007; Wang et al.,
2008.) The relationship between adiposity and risk of colon cancer appears to be
stronger with advancing age and among individuals with low levels of physical activity
(Moore et al., 2004.) No statistically significant relationships were found between
adiposity measures and rectal cancer incidence or death among men or women
(MacInnis et al., 2006; Pischon et al., 2006.)
Several hypotheses have emerged to explain the underlying mechanisms linking
obesity with colorectal cancer. Two schools of thought currently dominate the research:
(1) hyperinsulinemia pathway, and (2) chronic bowel inflammation by release of
inflammatory cytokines from visceral adipose tissue into the lumen of the bowel (Wisse,
2004; Calabro et al., 2008; Kim K et al., 2008; Kim S et al., 2008.) Adipose tissue was
long thought to be a passive storage facility for excess calories within the body (Visser et
al., 1999; Fantuzzi, 2005; Calabro et al., 2008), but recent research provides evidence
that adipose tissue, particularly central fat, is an active participant in regulating
endocrine and pathologic processes, including immunity and inflammation (Fantuzzi,
2005; Calabro et al., 2008.) Evidence has shown that adipose tissue regularly releases
cytokines (referred to as adipocytokines in this situation) such as C-Reactive Protein
(CRP), Interleukin-6 (IL-6), and Tumor Necrosis Factor-alpha (TNF-α), that create a
chronic low-grade inflammatory environment in the body locations proximal to fat
7

cells (Visser et al., 1999; Khaodhiar et al., 2004.) Furthermore, it has been observed that
macrophages tend to accumulate in the adipose tissue of obese individuals, leading to an
even greater inflammatory response by prompting an increase in adipocytokine secretion
by fat calls (Gunter et al., 2006.) Visceral adipose tissue, or fat cells that are located
around the waist and in between abdominal organs, seems to be more active and release
more cytokines than subcutaneous adipose tissue located in the extremities (Kim K et al.,
2008.) Numerous studies have shown that higher adiposity measures correlate well with
increased serum levels of inflammatory proteins (Fantuzzi, 2005; Kim K et al., 2008;
Wee et al., 2008.)

Correlations were more remarkable when measures of visceral

adiposity (i.e. waist circumference) were compared with inflammatory marker levels
than when measures of systemic adiposity (i.e. body mass index) were analyzed (Park H
et al., 2005; Kim S et al., 2008; Wee et al., 2008.)
To illustrate the lability of this association, several prospective longitudinal
studies on weight change and subsequent changes in inflammatory marker levels have
produced evidence that those participants who lost weight concomitantly lowered their
inflammatory marker levels and those who gained weight experienced an increase in
their inflammatory marker levels (Fogarty et al., 2008; Kim K et al., 2008.) Also,
regular use of non-steroidal anti-inflammatory drugs has been shown to confer a
markedly decreased risk of colorectal cancer, providing evidence that chemoprevention
of bowel inflammation protects against colon carcinogenesis (IARC, 1997; Grau et al.,
2009.) It is postulated that the chronic bowel inflammation induced by high visceral
obesity may promote an environment in which cell growth becomes dysregulated
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through oxidative DNA damage, eventually overriding apoptotic controls and increasing
likelihood of carcinogenesis (Gunter et al., 2006.)

1.6 C-Reactive Protein and Obesity
C-Reactive protein has been found to be a very promising biomarker for studying the
relationship between obesity and inflammation (Erlinger et al., 2004.) Park et al. (2005)
studied CRP levels in relation to several adiposity measures among Asian adults, finding
that CRP levels correlated strongly with abdominal obesity (Spearman’s coefficient for
waist circumference=0.75) and moderately with other measures of obesity (Spearman’s
coefficient= 0.65 for crude weight, 0.69 for body mass index, and 0.68 for waist-to-hip
ratio.)

C-reactive protein produced more significant correlations with adiposity

measures than any other inflammatory markers evaluated in the study. Similar yet
divergent results for the correlation of CRP and obesity were concluded in a study of
European adults by Rexrode et al. (2003.) This study also found a direct positive
relationship between CRP and obesity; however, the strongest correlation observed was
between CRP and body mass index, possibly indicating a difference in risk between the
two demographically diverse study populations. Overall, CRP proved to be a stronger
correlate of obesity than all other inflammatory markers measured in these two studies.

1.7 C-Reactive Protein and Colorectal Cancer
In addition to being a relatively consistent correlate of obesity, CRP has also
been found to be a more highly associated marker for colorectal cancer risk than other
inflammatory markers. A study by Il'yasova et al. (2005) examined the associations of
9

several inflammatory markers (C-Reactive Protein, Interleukin-6, and Tumor Necrosis
Factor-alpha) with the risk of site-specific cancers and found that the association of CRP
with colorectal cancer was more precise than the other two markers. Another study by
Groblewska et al. (2008) found C-Reactive Protein to be a better predictor for colorectal
cancer death than other inflammatory markers. Results of these studies suggest that, to
date, CRP may be the most useful inflammatory marker to study when assessing risk of
colorectal cancer incidence and death.

1.8 Conclusion
Ample evidence has linked higher levels of both obesity and C-Reactive Protein to
increased risk for colorectal cancer incidence and death.

Furthermore, C-Reactive

Protein levels and adiposity measures have shown a moderate positive correlation,
indicating that CRP may be linked with colorectal cancer through an obesity-induced
inflammation pathway. However, it remains unknown how the relationship between
CRP and obesity measures indicate risk of mortality and colorectal cancer among the
National Health and Nutrition Examination Survey III (NHANES III) participants. Is
CRP a risk factor for all-cause mortality, and more specifically death from colorectal
cancer, independent of obesity? It is hypothesized that NHANES III participants having
C-reactive protein levels greater than 0.50 mg/dL will incur a greater risk of all-cause
mortality and colorectal cancer mortality than participants with normal CRP values, and
that this relationship will persist after adjustment for adiposity measures. Using data
from NHANES III and the National Death Index, this investigation aims to:
(1) Describe demographic and lifestyle attributes of those with normal and
elevated levels of serum C-Reactive Protein,
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(2) Determine whether individuals with elevated C-Reactive Protein levels have
a greater risk of all-cause mortality and death from colorectal cancer compared to
individuals with normal CRP levels, and,
(3) Assess whether the relationship between CRP and all-cause mortality and
death from colorectal cancer is modified by controlling for different measures of
obesity (body mass index, BMI-W, waist circumference, and waist-to-hip ratio.)

2.0 METHODS

2.1 Study Population
We analyzed data from the National Health and Nutrition Examination Survey III
(NHANES III), the seventh of a series of studies conducted by the National Center for
Health Statistics designed to estimate the nation’s health status, assess the nationwide
prevalence of risk factors for disease, and contribute to an understanding of disease
etiology (NCHS, 1992; DHHS, 1996.)

The NHANES III sample population was

carefully constructed as a complex multistage probability sample to represent the total
civilian non-institutionalized US population aged 2 months and older (NCHS, 1992.)
39,695 persons were selected from 81 primary sampling units to be interviewed and
examined, with oversampling employed among the young, the elderly, and minorities to
facilitate statistically-powered investigations of these subsamples.

In two stages

conducted from 1988-1994, 33,994 people were interviewed (14% non-response) and, of
these, 30,818 participated in intensive physical examinations and blood draws for
laboratory measures (9% non-response) at the NHANES mobile examination center
(Mohadjer et al., 1996.) Additionally, because NHANES III was the first in the series
11

to investigate individuals older than 75 years of age, a new home examination technique
was developed to minimize non-response among this population (NCHS, 1994.)
Ultimately, 31,311 examinations were recorded in the NHANES III database, with due
care being exercised on the part of medical examiners and laboratory personnel to ensure
continuity of exam protocol and proper handling and storage of body fluid specimens
(Gunter et al., 1990.) NHANES III methodologies and study participants have been
described in detail elsewhere (Mohadjer et al., 1996.)

2.2 Sample Weights in NHANES III
The complex multistage probability sample employed in NHANES III requires that
statistical analyses take into account: differential probabilities of selections among
subgroups, bias from non-response, and need to reflect the dimensions of target
population make-up (Mohadjer et al., 1996.)

This adjustment is accomplished by

assignment of multiple weights to each individual, thereby allowing generalization of
findings to the U.S. population as a whole. Sample weighting was carried out in three
stages.

First, a basic weight was calculated to compensate for three factors: the

individual’s age/sex/race-ethnicity domain, the density stratum, and the primary
sampling unit (Mohadjer et al., 1996.) Second, a weight was applied to account for nonresponse (Figure 1) of individuals at both the interview and examination stages after
allocating non-responding individuals to classes such as race/ethnicity, age, household
size, and self-reported health status (NCHS, 1992.) A third weight was applied to all
survey participants based on post-stratification of the sample weights in accordance with
1990 census bureau estimates of the U.S. population (Mohadjer et al., 1996.)
12

Combining the basic weight, non-response adjustment weight, and post-stratification
adjustment weight with a 4th weight that compensated for differences between Phase 1
(1988-1991) and Phase II (1991-1994) samples created the overall weight for each
individual studied in NHANES III. For the purposes of this investigation, final weight
“Final MEC+Home exam” (SAS weight code wtpfhx6) was employed to individuals
who were interviewed and examined either at the mobile examination center or at home,
and who were surveyed during either phase of the sampling periods (Mohadjer et al.,
1996; DHHS 1996.)

2.3 NHANES III database linked with the National Death Index
In order to transform NHANES III from a cross-sectional study into a prospective study
with an outcome endpoint, the National Center for Health Statistics linked the NHANES
III database with mortality data records from the National Death Index (NDI) through
December 31, 2000, resulting in a follow-up time for mortality status ranging from 6 to
12 years (Madans et al., 2006; NCHS, 2005.) This data linkage was performed through
probabilistic matching, with one or more of these criteria sufficing to produce a match:
(1) social security number, (2) first and last name, exact month of birth, year of birth
within 1 year, (3) last name, first and middle initials, exact month of birth, year of birth
within 1 year, (4) first and last name, exact month and day of birth, (5) last name, first
and middle initials, exact month and day of birth, (6) first name, father’s surname, exact
month and year of birth, and (7) for females only, first name, exact month and year of
birth, and last name from the survey record matching the birth surname on the NDI
record (NCHS, 2005.) Mortality status of NHANES III participants could also be
13

determined if a death certificate was directly received by NCHS and matched with a
NHANES III survey record based on name and other linkable information such as
occupation (NCHS, 2006.) We used the public data files accessible on the NCHS
website which included information on follow-up eligibility status, mortality status,
mortality status source (NDI or death certificate), person-months of follow-up time from
interview and exam, and underlying cause of death (NCHS, 2006.) Underlying cause of
death was established through use of ICD-9 codes through 1998 and ICD-10 codes for
1999-2000, but final cause of death data were organized via ICD-10 codes after
adjusting for changes between the coding systems (NCHS, 2006.) At the end of the
follow-up period, 3,384 adult NHANES III participants were assumed to be deceased
through NDI linkage (NCHS, 2005.)

2.4 Eligibility Criteria
Individuals in the NHANES III population were determined to be eligible for this study
if they were 50 years of age or older, had a known mortality status, and had valid data on
covariates and outcomes. Values of “blank but applicable,” “blank,” and “I don’t know”
were re-categorized as missing data. From the initial NHANES III sample of 33,994,
our study included 7,589 participants with valid baseline data, laboratory assay results
for CRP, and NDI mortality follow-up (Figure 1.)

2.5 Study Groups
This study compares two study groups: (1) individuals with a serum C-reactive protein
(CRP) level of <.50 mg/dL (normal) and (2) individuals with a serum C-reactive
14

protein level of .50 mg/dL or greater (high.) This cutoff point for normal versus high Creactive protein was employed in colon cancer studies conducted by Koike et al., (2008)
and Shiu et al., (2008.) C-reactive protein was measured during the NHANES III
laboratory examination (DHHS, 2007.) Serum C-reactive protein was analyzed using a
fully automated Behring Nephelometer Analyzer System (Behring Diagnostics, Inc,
Somerville, NJ.) Extensive details about the specific methods for obtaining C-reactive
protein levels for the NHANES III population are provided elsewhere (Gunter et al.,
1996.)
Participants were further classified according to three commonly used adiposity
measures: body mass index (BMI), waist circumference (WC), and waist-to-hip ratio
(WHR.) We also employed an adiposity measure developed in 1998 by the National
Heart, Lung, and Blood Institute that stratifies BMI categories by waist circumference,
which we refer to as BMI-W (NHLBI, 1998; Figure 3.) Body measurements were taken
by trained NHANES III examiners using specified protocols (DHHS, 1996.) Body mass
index was calculated by dividing an individual’s weight in kilograms by height in meters
squared. Categorization of BMI in our study used standard breakdowns (NHLBI 1998),
as follows: [1] normal (BMI 18.5-24.9), [2] overweight (BMI 25.0-29.9) and [3] obese
(BMI 30.0+.) Underweight individuals (BMI < 18.5) were excluded from analysis.
Waist circumference was calculated by measuring the circumference of the abdomen in
centimeters at the natural waist, around the bellybutton. Per accepted criteria (NHLBI
1998), waist circumference was classified as high if a male participant’s waist
circumference measured >102 cm at the bellybutton or a female participants’ waist
circumference measure >88 cm at the bellybutton. Waist-to-hip ratio was calculated
15

by dividing the waist circumference in centimeters by the hip circumference (measured
at the widest point of the hips) in centimeters. A WHR greater than 1.0 was considered
high for males and a WHR greater than 0.9 was considered high for females in this study
(NHLBI, 1998.) As depicted in Figure 3, BMI-W consists of five categories: [1-normal]
BMI (18.5-24.9) and any waist circumference); [2-increased] BMI (25.0-29.9) and waist
circumference (normal); [3-high] BMI (25.0-29.9) and waist circumference (high) or
BMI (30.0-34.9) and waist circumference (normal); [4-very high] BMI (30.0-34.9) and
waist circumference (high) or BMI (35.0-39.9) and any waist circumference); and [5extremely high] BMI (40.0+) and any waist circumference.

2.6 Outcomes
Mortality status (i.e., dependent variable) was categorized according to two schemes: [1]
alive and deceased from any cause, and [2] alive, deceased from colorectal cancer
(CRC), deceased from other obesity-related cancers (oORC), and deceased from other
causes (Other.) The first scheme used the existing variable (mortstat) in the NDI-linked
data file. The second was created using ICD-10 codes for underlying cause of death
(ucod_113) in the NDI-linked mortality data file. The “alive” category was assigned
when “mortstat”=0 and “ucod_113”=missing. The “CRC” category was assigned to
values where “mortstat”=1 and “ucod_113”=023, representing codes C18-C21
(malignant neoplasms of the colon, rectum, and anus) in the ICD-10 codes (NCHS,
2006.)

The “oORC” category was assigned to values where “mortstat”=1 and

“ucod_113”= 025 (representing ICD-10 code C25, malignant neoplasms of the
pancreas), 029 (representing ICD-10 code C50, malignant neoplasms of the breast),
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031 (representing ICD-10 codes C54-55, malignant neoplasms of the corpus uteri and
uterus), and 033 (representing ICD-10 cod C61, malignant neoplasms of the prostate;
NCHS, 2006.) The “Other” category was assigned to all values where “mortstat”=1 and
“ucod_113” did not equal satisfy any of the above values (023, 025, 029, 031, 033.)

2.7 Statistical Analyses
All statistical analyses for this study were performed using SURVEY procedures
available in SAS that incorporate essential survey information such as sample weights
and stratification in analyses of data sets from complex multistage probability sampling
techniques (An, 2002; Jones et al., 2006.) Descriptive analyses (Aim 1) were performed
for: age, gender, race/ethnicity, tobacco use, alcohol use, non-steroidal antiinflammatory drug use, and personal history of selected diseases in relation to CRP
level, using t-tests for continuous data and chi-square tests for proportions.
Mortality risk related to CRP level (Aim 2) was assessed by Dichotomous
Logistic Regression for any cause of death, and, Polytomous Logistic Regression when
multiple outcomes were studied (i.e., death from colorectal cancer, death for other
obesity-related cancers, death from all other causes.) We performed univariate, ageadjusted and multivariate-adjusted odds ratios. Separate analyses also were performed
to examine the relationships between each of the adiposity measures and mortality risk.
Covariates in the multivariate models are defined as follows: Age was considered as a
continuous variable in the multivariate model; Sex (male and female); Race/ethnicity
(white

non-Hispanic,

black

non-Hispanic,

Mexican-America,

and

other.)This

unconventional categorization comes from an existing variable in the original
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NHANES survey, which purposefully oversampled Mexican-Americans; Cigarette use
(never, past, or current) according to answers given to the interview questions “Have you
smoked more than 100 cigarettes in your lifetime?” and “Do you smoke now?”; Alcohol
use (never, past, or present) according to answers given to the interview questions “Have
you had more than 12 alcoholic drinks in your lifetime?” and “Have you had more than
12 alcoholic drinks within the last year?”; Physical Activity (more active than others,
less active than others, or about the same as others) according to answers given to the
question, “Compared to others your age, how would you rate your physical activity
level?”; NSAID (yes or no) according to responses given to the question “Have you
taken NSAIDS (aspirin, acetaminophen, ibuprofen, naproxen, etc.) within the last
month?”; and, Personal History (yes, no) of cancer, cardiovascular disease, and diabetes
was determined by responses to multiple questions specifically asking the respondents if
they had been told by a doctor that they had cancer, cardiovascular disease (heart attack,
congestive heart failure, etc), or diabetes. To determine if observations regarding CRP
held when controlling for body measures of adiposity (Aim 3), multivariate models
defined above also included adiposity measures as covariates each in a separate analysis.
Results for all tests were considered statistically significant if p<0.05 or results
within the confidence intervals (95%) did not include 1.0. SAS 9.2 was used to perform
all statistical analyses of NHANES III data in this investigation (SAS, 2008.)
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3.0 RESULTS
3.1 Participant Characteristics
CRP Status. Baseline characteristics for all eligible participants (n=7192) according to
CRP level (Normal vs. High) are shown in Table 1. Proportionately there were more
females than males in the High-CRP group (29.34% vs. 23.29%, p=.0007.)

Non-

Hispanic blacks and Mexican Americans were more likely to be in the High-CRP group
than Non-Hispanic whites and those categorized as "other" (38.01% and 28.93% vs
25.75% and 21.76%, respectively, p<.0001.) There were more current drinkers in the
normal-CRP group than in the high-CRP group (77.12% vs. 22.88%p=.0020.)
Participants in the normal CRP-group were much more likely than those in the high-CRP
group to consider themselves physically active (44.23% vs. 28.79%, p<.0001.)

A

marginal difference between the two groups was observed in relation to tobacco use
(p=.06.) Age, non-steroidal anti-inflammatory use, and having a personal history of
cancer did not differ significantly between the two study groups.
Participants with higher levels of adiposity were more likely than those with
normal weight to exhibit elevated CRP levels (Table 2.) For example, participants with
categorized as having normal or overweight BMI were more likely to have normal CRP
levels compared to obese individuals (82.16%,, 75.13%, 40.14%, respectively, p<.001.)
Participants in the high-CRP group were also more likely to have a high waist
circumference and waist-to-hip ratio than did the normal-CRP group (p<.0001.)
Similarly, participants with high-CRP levels were more likely to have higher-risk BMIW values (3-high, 4-very high, 5-extremely high) than the normal-CRP group.
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Spearman’s correlation coefficients between CRP level and adiposity measures showed
a weak positive relationship (Table 3.)
All-Cause Mortality. Table 4 illustrates patient characteristics according to mortality
status based on the National Death Index linkage with the NHANES III database.
Participants varied according to mortality status on almost all demographic and
behavioral factors, as well as CRP level. For example, males were more likely to be
deceased than were females, and Non-Hispanic Whites and non-Hispanic Blacks were
more likely to be deceased than Mexican Americans and those categorized as Other. As
expected, increasing age was a significant correlate of mortality with the youngest age
group (50-54) being much less likely to be deceased than the oldest age group (80+;
6.55% vs. 70.79%, respectively) with increasing mortality continually observed as age
group increased (<.0001.)
With regard to CRP status and mortality, individuals with elevated CRP levels at
baseline were much more likely to be deceased at the end of follow-up than those with
normal CRP levels.

Participants who had classified themselves as current or past

smokers were more likely to be deceased at end of follow-up (27.63% and 26.64% vs.
22.35%, respectively), while current alcohol drinkers and those who reported taking
NSAIDS within the last month were more likely to be alive at the end of follow-up.
High physical activity rates also seemed to be protective against death. Individuals
reporting a personal history of cancer, cardiovascular disease and diabetes were more
likely to die than those who had not. Contrary to evidence citing high adiposity as a risk
factor for mortality, participants with high BMI, BMI-W, and waist circumference
values were more likely to be alive at the end of follow-up than those with normal
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values (p<.0001.) Those with high waist-to-hip ratio values were slightly more likely to
die by the end of follow-up than those with normal waist-to-hip ratio, but this
relationship was not significant (p=0.72.)
Cause-Specific Mortality.

In Table 5, we broke down mortality into four specific

outcomes: Alive, Death from colorectal cancer (CRC), Death from other obesity-related
cancers (Other-ORC), and death from all other causes (All Other Causes.) Compared to
females, males were more likely to die (p=.0408) from other obesity-related cancers
(1.39% vs. 0.98%), colorectal cancer (0.64% vs. 0.53%) and all other causes (24.84% vs.
21.96%.) A higher proportion of Individuals with high-CRP died from CRC, other
obesity-related cancers and all other causes compared to those with normal CRP level
(p<.0001.) Surprisingly, individuals with normal BMI, waist circumference, BMI-W,
WHR levels tended to die in greater proportions than individuals with higher values
(p<.0001.) Although the specific cause of death varied somewhat according to tobacco
smoking history (p=.0005), there appeared to be no coherent trend between ever use
(past or current) and never use. Similarly, cause of death varied according to alcohol use
(p<.0001) but with no clear trend in relation to ever (past or current) versus never use.
Current NSAID use was not associated with a consistently greater proportion of deaths
across the types of deaths.

3.2 CRP Status and Mortality Risk
All-Cause Mortality. Crude, age-adjusted, and multivariate-adjusted odds ratios for
mortality are shown in Table 6. Part A of Table 6 displays results from the conventional
dichotomous logistic regression. Compared to patients with normal CRP levels, those
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with high CRP levels had an approximately 60% increase in risk of death as seen in both
the crude and age-adjusted analyses. This risk was attenuated to approximately a 30%
increased risk of death after adjustment for the following suspected confounders: sex,
age, race/ethnicity, tobacco use, alcohol use, physical activity level, NSAID use, and
personal history of cancer, cardiovascular disease, or diabetes. Analyses were conducted
with each adiposity measure added as a covariate in separate multivariate models. Odds
Ratios for mortality risk in relation CRP levels did not appreciably change (See Table 7
Part A) when controlling for adiposity measures. Most of the adiposity measures were
associated with increased risk of death in the multivariate models. Some measures,
however, were associated with a decreased risk of death.
Cause-Specific Mortality.

Part B of Table 6 includes the odds ratios for CRP level in

relation to the four outcome groups (Alive, CRC, Other-ORC, and All Other Causes.)
Due to having more than two outcomes, Polytomous Logistic Regression was employed
using a referent group consisting of participants with normal CRP level (versus high
CRP) who were still alive at the end of follow-up which was compared, in parallel, to
normal-versus-high CRP with respect to each mortality outcome. Participants with
elevated CRP levels had a greater than two-fold risk of dying from colorectal cancer
(2.66 OR, 95% CI=1.28-5.24) compared to participants with normal CRP levels who
were still alive. Age adjusted odds ratios for cause-specific mortality among the highCRP group were 2.723 (95%CI=1.297-5.719) for death from colorectal cancer, 1.403
(.810-2.430) for other obesity-related cancers, and 1.619 (1.375-1.906) for the death
from all other causes.

After adjusting for the same confounders as those in the

dichotomous logistic regression, individuals with high CRP were two and half times as
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likely to die from colorectal cancer (2437, 95%CI= 1.203-4.938), 21% more likely to die
from other obesity-related cancers (1.212, 95%CI= 0.626-2.344), and 30% more likely
to die from other causes (1.304, 95%CI= 1.059-1.607.)
Part B of Table 7 shows the odds ratios for cause-specific mortality after adding
adiposity measures to the multivariate model used above. Adjustment for BMI indicated
odds ratios for cause-specific mortality among the high-CRP group of 2.462 (95%
CI=1.191-5.088) for deaths from colorectal cancer, 1.174 (95% CI= 0.610-2.260 NS) for
deaths from other obesity-related cancers, and 1.392 (95% CI=1.123-1.725) for death
from all other causes. Adjustment for BMI-W resulted in the high-CRP group having a
2.765 times (95%CI=1.295-5.904) increased risk for death from colorectal cancer, a 26%
(1.261, 95% CI=0.645-2.63 NS) increased risk for death from other obesity-related
cancers, and a 42% (1.418; 95% CI= 1.155-1.741) increased risk for death from all other
causes.

Adjustment for waist circumference resulted in odds ratios of 2.849

(95%CI=1.313-6.183) for death from colorectal cancer, 1.295 (95% CI=0.672-2.494) for
death from other obesity-related cancers, and 1.349 (95% CI= 1.099-1.656) for death
from all other causes. Finally, after adjusting for waist-to-hip ratio, the odds ratios for
the individuals in the high-CRP group were found to be 2.867 (95% CI=1.317-6.243) for
death from colon cancer, 1.214 (95%CI= .621-2.372) for death from other obesityrelated cancers, and 1.302 (95% CI=1.047-1.618.)
Regarding adiposity as an independent risk factor for all-cause mortality (Table
8), we found in multivariate analyses that BMIs in the range of overweight and obese
were significantly associated with reduced risk of death (OR=0.79, 95% CI 0.63-0.99;
OR=0.65 95% CI 0.52-0.81, respectively.) Likewise, BMI-W levels tended to be
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associated with reduced risk of death as was waist circumference in multivariate
analyses (OR=0.81, 95% CI 0.69-0.94.) On the other hand, elevated waist-to-hip ratio
was associated with increased risk of death in both crude and age-adjusted analyses, but
this effect was attenuated in the multivariate analysis. When examining adiposity as a
risk factor for specific causes of death (Table 9), we observed no consistent patterns.
Surprisingly, in some analyses, data suggested that adiposity may be protective for
various causes of death.

4.0 DISCUSSION

4.1 Key Findings
In this study, we examined the effect of C-reactive protein level on colorectal cancer
mortality, and if this relationship remained independent of obesity status. In terms of
correlates of CRP (Aim 1), we found that individuals with elevated CRP differed from
individuals with normal CRP in terms of sex, race/ethnicity, alcohol use, physical
activity level, and personal history of cardiovascular disease and diabetes. Tobacco use
marginally different among the two groups (p=.06.)

Age, non-steroidal anti-

inflammatory drug use, and personal history of cancer, however, did not differ
significantly between the two study groups.
We found evidence that individuals with elevated C-reactive protein levels were
at greater risk for both all-cause mortality and death from colorectal cancer (Aim 2) in
both univariate and age-adjusted analyses. An attenuated but still statistically significant
risk of all-cause mortality and colorectal cancer mortality was maintained in multivariate
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analyses controlling for logistic regression to account for differences in covariates
between the two study groups found through study aim 1. These findings are consistent
with results reported in a recent study by Heikkila et al. (2009) examining the
association between CRP and colorectal cancer risk among English men aged 45-59 and
English women aged 60-80.
Consistent with our hypotheses, we found that elevated CRP levels were
associated with a statistically significant increase in risk of all-cause death and death
from colorectal cancer independent of obesity status, regardless of which body measure
of adiposity was analyzed.

Controlling for body mass index, BMI-W, and waist

circumference yielded slightly attenuated odds ratios, while controlling for waist-to-hip
ratio slightly increased the odds ratio estimates.
Very surprisingly, we found either no association of obesity with mortality risk,
or in some sub-analyses, results suggested that high anthropometric measures of
adiposity may actually be protective against all-cause mortality and colorectal cancer
death.

These findings are in stark contrast to the overwhelming preponderance of

evidence in the literature that states that obesity confers a greater risk of all-cause
mortality and colorectal cancer mortality. To further explore these novel findings, we
compared our findings of the correlates of CRP and adiposity measures with results
obtained in previous studies. Correlations between CRP levels and adiposity measures
performed in previous studies have shown strong positive relationships; however,
correlations conducted in our investigation yielded much weaker associations.

For

example, Park et al. (2005) reported Spearman correlation coefficients of 0.69 between
CRP and BMI, 0.75 between CRP and waist circumference, and 0.68 between CRP
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and waist-to-hip ratio among an Asian population with no pre-existing inflammatory
conditions or symptoms. The correlation between CRP and BMI-W was not performed
in the study by Park. Correlations between CRP and adiposity measures in our study
were much lower, ranging from 0.07 to 0.17. We speculate that our unusual findings
may be due to a number of causes. Park et al. (2005) excluded individuals who had very
high CRP levels (mg/dL > 10.0), which are indicative of acute infection or trauma.
Inclusion of these very high values in our study may have resulted in a lack of
correlation between very high CRP levels and very high adiposity measures, especially
since those with acute sickness tend to lose body mass over time and exhibit normal or
even below normal adiposity measurements (Flegal et al., 2007; Manson et al., 2007.)
To demonstrate the possible effect that the inclusion of individuals with very high CRP
levels may have had on the correlations, we performed another correlation excluding all
participants with CRP levels greater than 10 mg/dL. This exclusion resulted in slightly
higher correlation coefficients but did not increase them sufficiently to match the
correlations observed in other studies.

On the other hand, we suspected that the

preponderance of CRP values labeled as "undetectable" (<.22 mg/dL), that resulted from
the relative low-sensitivity of the assay used to measure CRP, may have also diluted the
correlation coefficients. However, upon exclusion of participants with undetectable
levels of CRP, we found that the correlation coefficients between adiposity measures and
CRP became marginally negative. Although we did not ascertain an explanation of our
unusual findings with respect to correlation coefficients, the results of the categorical
analyses between adiposity measures and CRP levels in our study did show statistically
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significant associations between increased CRP level and increasing adiposity measures.
Another possible reason for the null effects of increasing adiposity on mortality
may be that the increased risk of obesity-related negative outcomes may be eliminated
by the use of treatment modalities that decrease the negative effects of obesity on one's
health. For example, increased use of anti-inflammatory drugs during the follow-up
period may have distorted the relationship between CRP and obesity measures by
controlling inflammation brought upon by increased adiposity. Consistent with this
hypothesis, Wee et al. (2008) observed CRP levels to be only weakly correlated with
adiposity measures when a large proportion of the study population was on a low-dose
NSAID regimen. Due to the increase in attention by the media advocating use of a lowdose aspirin regimen for prevention of multiple diseases since baseline data were
collected, participants that may have started to use NSAIDS during follow-up time may
not have reported regular NSAID use at baseline.
A third possible explanation for lack of correlation between CRP and adiposity
measures is misclassification of adiposity in the NHANES III cohort due to longitudinal
changes in participants’ obesity levels after the baseline measurement. In the time
period following the data collection for NHANES III (1988-1994), there was a
substantial surge in obesity prevalence throughout the country (CDC, 2008.)

The

baseline measurements of adiposity, hence, may not accurately represent the obesity
status of NHANES III individuals during the follow-up period, which occurred between
6 and 12 years from collection of baseline data.
If misclassification is at play, is it possible, however, that obesity-related
sequelae would be manifest so quickly? Research documenting the effects of weight
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loss on improved short-term health outcomes provides evidence that alterations in body
size such as weight gain could have immediate deleterious effects on health.

An

example of this is the effect seen in a study by Eliassen et al. (2006) among women aged
30-55 with a mean follow-up time of 24 years that found a 2 kg weight gain since age 18
conferred a 24.2% greater risk breast cancer (long-term risk), while a 2 kg weight gain
among the same women within a few years after menopause conferred a 7.6% increase
in risk of developing breast cancer.

It is possible that many of the NHANES III

participants whose adiposity measures were “normal” at baseline gained sufficient body
mass over the course of follow-up to confer increased risk of mortality from obesityrelated diseases such as colorectal cancer. Therefore, differences in outcomes across the
study groups converged towards the null. Misclassification of individuals as having had
“normal” body size when they should have been characterized as having high adiposity
later in the study may account for a null or protective effect of increased body size on
mortality risk.
We posit that that the hypothesis of misclassification of adiposity measures in
NHANES III participants is supported by results from a study by Flegal et al. (2007),
who found that overweight and obesity was a risk factor for deleterious outcomes among
the NHANES I cohort (1971-75), a longitudinal study with repeated measurements and
conducted in an earlier and more weight-stable time period yet overweight status was
found to be a protective factor against death in the NHANES II and III cohorts. Flegal
(2007) speculated that a large proportion of the difference between cohorts could be
explained through increased use of treatment modalities that are superb for managing
chronic conditions associated with obesity, such as blood sugar-stabilizing drugs for
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obese diabetics and prophylactic low-dose aspirin use among obese individuals who are
at risk for inflammation-related diseases such as cardiovascular disease. On the other
hand, obesity rates are higher among lower socio-economic classes and the underserved
(Stunkard et al., 1993.) Hence, use of beneficial treatments might not fully explain the
lack of relationship between obesity and mortality observed in the NHANES III cohort.
It remains unknown to what extent these different hypotheses explain the unusual
relationships between obesity and mortality risk observed in our study. We must also
ask the question about reliability of the participants’ CRP levels over time as well. CRP
level is well-known to increase with age and thus follow-up time (Rumley et al., 2006.)
Furthermore, CRP has been documented to be a marker for both long- and short-term
mortality risk, while the time-based effects of adiposity and weight gain remain
inconclusive. Therefore, it is plausible that relative levels of CRP likely remained
consistent.

Hence, the risks of all-cause and colorectal cancer-specific mortality

conferred by high levels of CRP might have remained relatively consistent through
follow-up period.

4.2 Strengths and Limitations
A major strength of this investigation is the use of data from the NHANES III study, a
complex multi-stage probability sample that is representative of the U.S. population
enabling generalization of study results to all Americans. Meticulously constructed
linkage standards for connecting NHANES III baseline data with National Death Index
data assured that individuals who were assumed to be alive at the end of follow-up were
correctly classified. Furthermore, the comprehensiveness of methods for collecting
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baseline measurements used in NHANES III lends credence to the reliability of the
anthropometric measures and lab-assigned values for C-reactive protein (Gunter et al.,
1990; NCHS, 1992.) Lastly, ample follow-up time (mean=96.5 months) was allotted so
that a sufficient numbers of deceased participants (n=3384) accrued.
There are several important limitations to be considered. First, as discussed,
NHANES III collected baseline measurements of all variables only once, while more
reliable findings may have been observed if repeated measurements of the independent
variables had been accumulated. This limitation is especially pertinent when analyzing
adiposity values in the context of a rapidly growing obesity epidemic.
Another limitation of this study is that only mortality status, not disease
incidence, was obtained during the follow-up period. Therefore, the results of this study
cannot be assumed to reflect risk of colon cancer incidence, which is more common than
colorectal cancer death and may produce serious quality of life issues independent of
mortality risk. Also, the multivariate model might have benefited from inclusion of
more key risk factors for colorectal cancer death not available in the NHANES III data
sets we analyzed, such as history of use of statins or dietary history (e.g., high red meat
intake.) Furthermore, numerous studies have shown that increased CRP and adiposity is
associated with colon cancer but not significantly associated with rectal or anal cancers
(MacInnis et al., 2006; Larsson et al., 2007.) However, mortality data for death from the
National Death Index was only available for 113 aggregated groups of ICD-10 code
subgroups.

Only mortality from colorectal cancers (as a group) was available for

analysis in this investigation. Therefore, we speculate that the findings in our study may

30

be underestimated when compared to results that would have been observed if only
death from colon cancer had specifically been analyzed.

4.3 Conclusions
Findings from this investigation suggest that individuals with high levels of serum Creactive protein may have an increased risk of all-cause mortality, colorectal cancer
death, and death from other obesity-related cancers. This increased risk seems to persist
even after adjusting for many potential confounding variables including anthropometric
measures of adiposity. We speculate that the negligible change in mortality risk after
controlling for baseline adiposity status may be due, in part, to increased adiposity of
participants over time and subsequent misclassification of participants based on baseline
data. More research using different study populations is warranted to further investigate
the links between C-reactive protein, obesity, and colorectal cancer. Several
opportunities for future analysis of this topic have been identified:
1. Continue to review and analyze extant published findings using NHANES III
data regarding risk of mortality in relation to adiposity measures to determine
if our findings are consistent.
2. Perform survival analyses to identify any differences in the length of time to
mortality
outcomes.
4. Explore genetic determinants of CRP serum levels among NHANES III
participants using the restricted-access polymorphism database available
through the Research Data Center at the National Center for Health Statistics.
5. Identify an existing longitudinal cohort study in which CRP, obesity status,
and long-term outcomes can be analyzed.
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Further exploration of these topics may provide a greater understanding of the
inter-relationships of C-Reactive Protein, adiposity measures, and colorectal cancer,
leading to effective preventive programs that will improve the public health.
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6.0 FIGURES and TABLES

Fig. 1 Formation of Study Sample Size in NDI-linked NHANES III Database
81 primary sampling counties

89 survey locations (nationwide)

2144 segments

93,653 households screened

39,695 persons selected for interview

 14% non-response
33,994 persons participated in interview

 9% non-response
31,311 participated in examination & lab

7593 persons aged 50+ years

 <1% loss to follow-up
7589 persons with NDI follow-up
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Fig. 2 Study Design
NHANES III participants
aged 50+ with follow-up
data (n=7589)

Normal C-reactive protein
(<=.50 mg/dL; n=4977)

Deceased
(n=1509)

DeceasedCRC
(n=38)

DeceasedoORC
(n=67)

Alive
(n=3468)

Deceasedother
(n=1402)

High C-reactive protein
(>.50 mg/dL; n=2115)

Alive
(n=1306)

Deceased
(n=807)

DeceasedCRC
(n=24)

DeceasedoORC
(n=40)

Key:
CRC- colorectal cancer
oORC= other obesity-other obesity related cancers
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EXPOSURE

OUTCOMES

Deceasedother
(n=743)

Fig. 3 Classification of the NIHLB BMI-W Index

BMI3

(disease risk)
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Circumference2,3

Average (1)

Any
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Any

18.5-24.9

Normal

25.0-29.9

BMI-W1

Increased (2)
High (3)

High
Normal

Very High (4)

High
Any

Extremely High (5)

1.
2.

3.

Any

BMI Label3
Underweight (1)
Normal (2)
Overweight (3)

25.0-29.9

Overweight (3)

30.0-34.9

Obese I (4)

30.0-34.9

Obese I (4)

35.0-39.9

Obese II (5)

40.0+

Obese III (6)

High waist circumference defined as: Males > 40 in (102 cm); Females > 35 in (88 cm)
National Institutes of Health, Expert Panel. Executive summary of the clinical
guidelines on the identification, evaluation, and treatment of overweight and obesity
in adults. Arch Intern Med. 199;158(17):1855-67.
Balkau B, Charles MA, Drivsholm T, et al. Frequency of the WHO metabolic
syndrome in European cohorts, and an alternative definition of an insulin
resistance syndrome. Diabetes Metab 2002;28(5):364-376.
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Table 1 Participant Characteristics according to C-Reactive Protein Level
C-Reactive Protein
Normal
(n=4977)

Sex
Male
Female
Race/Ethnicity
Non-Hispanic White1
Non-Hispanic Black
Mexican American
Other
Age
Mean (SD)
Age
50-54
55-59
60-64
65-69
70-74
75-79
80+
Smoking Status
Never
Past
Current
Alcohol Use
Never
Past
Current
Physical Activity Level
More active than others
About the same as others
Less active than others
Current NSAID use
Yes
No
Positive Personal History
Cancer
Cardiovascular Disease
Diabetes

High
(n=2115)

Chi-sq2

p-Value

2457 (76.71)1
2520 (70.66)

940 (23.29)
1175 (29.34)

11.46

.0007

2925 (74.25)
897 (61.99)
963 (71.07)
192 (78.24)

1104 (25.75)
534 (38.01)
418 (28.93)
59 (21.76)

23.96

<.0001

67.79 (10.76)

68.00 (10.63)

-0.772

.4426

656 (75.11)
617 (74.73)
806 (73.09)
739 (73.02)
741 (72.50)
474 (72.31)
944 (70.89)

257 (24.89)
253 (25.27)
360 (26.91)
333 (26.98)
310 (27.50)
198 (27.69)
404 (29.11)

3.79

.7056

2332 (75.39)
1799 (72.54)
846 (70.67)

893 (24.61)
771 (27.46)
451 (29.33)

5.68

.0585

988 (71.52)
2015 (71.33)
1657 (77.12)

437 (28.48)
932 (28.67)
565 (22.88)

12.40

.0020

1971 (80.91)
2045 (71.42)
816 (61.09)

568 (19.09)
938 (28.58)
554 (38.31)

99.43

<.0001

3354 (72.79)
1578 (74.83)

1449 (27.21)
650 (25.17)

2.38

.1233

764 (73.18)
767 (63.35)
612 (61.60)

315 (28.81)
475 (36.65)
421 (38.40)

0.02
31.65
31.59

.8886
<.0001
<.0001

1

n(%); percentages are weighted and rounded.
Rao-Scott Chi-square used to correct for weighted frequencies except for age as a
continuous variable, where t-test is used.
2
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Table 2 Adiposity Measures according to C-Reactive Protein Level
C-Reactive Protein

Body Mass Index
Normal
Overweight
Obese
Waist Circumference
Normal
High
BMI-W4
1- Normal
2- Elevated
3- High
4- Very High
5- Extremely High
Waist-to-Hip Ratio5
Normal
High
1
2

Chi-sq2

p-Value

498 (17.84)
786 (24.87)
779 (40.14)

149.05

<.0001

2453 (81.82)
2376 (66.65)

722 (18.18)
1314 (33.35)

85.17

<.0001

1803 (82.16)
828 (82.09)
1141 (70.64)
932 (62.83)
62 (32.46)

498 (17.84)
260 (17.91)
526 (29.36)
620 (37.17)
120 (67.54)

186.72

<.0001

2141 (78.79)
2585 (69.66)

745 (21.21)
1216 (30.34)

28.80

<.0001

Normal
n= 4843

High
n=2063

1803 (82.16)1
1990 (75.13)
1050 (59.86)
3

n(%); percentages are weighted and rounded.
Rao-Scott Chi-square used to correct for weighted frequencies.

3

High waist circumference >= 102 cm for men, >= 88 cm for women
Body Mass Index stratified by waist circumference (BMI-W)
5
High waist-to-hip ratio >= 1.0 for men, >=0.9 for women
4
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Table 3 Correlations1 between C-Reactive Protein and Adiposity Measures
1

Spearman correlations for ordinal data

C-Reactive Protein

P-Value

0.17

<.0001

BMI-W2

0.19

<.0001

Waist Circumference

0.14

<.0001

Waist-to-Hip Ratio

0.07

<.0001

Body Mass Index

2

Body Mass Index stratified by waist circumference (BMI-W)

Table 4 Participant Characteristics and All-Cause Mortality
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1

n (%); weighted and rounded percentages.
Alive
(n=5028)

Sex
Male
Female
Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Mexican American
Other
Age at Interview
Mean (SD)
Age at Interview
50-54
55-59
60-64
65-69
70-74
75-79
80+
Body Mass Index3
Normal (18.5-24.9)
Overweight (25.0-29.9)
Obese (30.0+)
BMI-W4
1- Normal
2- Elevated
3- High
4- Very high
5- Extremely high
Waist Circumference5
Normal
High
Waist-to-Hip Ratio6
Normal
High
C-reactive Protein (mg/dL)
Normal- (<0.5)
Elevated- (>0.5)
Smoking Status
Never
Past
Current
Alcohol Use
Never
Past
Current
Physical Activity Level
More active than others
About the same as others
Less active than others
Current NSAID use
Yes
No
Positive Personal History
Cancer
Cardiovascular Disease
Diabetes
Follow-up Time in Months
Mean (SE)7
Median

DeceasedAlive

n=5022CRC

(n=68)

DeceasedoORC
Deceased
(n=122)
n=2567

2237 (73.12)1
2785 (76.49)

1378 (26.88)1
1189 (23.51)

2645 (74.37)
1076 (69.26)
1075 (81.29)
226 (89.06)

1621 (25.63)
544 (30.74)
362 (18.71)
40 (10.94)

64.47 (9.38)

75.14 (9.77)

872 (93.45)
794 (88.34)
1013 (84.93)
833 (75.13)
743 (69.59)
363 (51.74)
404 (29.21)

78 (6.55)
124 (11.66)
216 (15.07)
304 (24.87)
382 (30.41)
378 (48.26)
1085 (70.79)

1500 (72.12)
196 (76.07)
1481 (80.17)

Deceased-Other 2
Chi-Square
(n=2375)

2
Chi-sqP-Value
P-Value

7.04

.0080

50.96

<.0001

-46.222

<.0001

712.68

<.0001

975 (27.88)
950 (23.93)
480 (19.83)

24.58

<.0001

1516 (72.12)
767 (76.24)
1202 (76.95)
1253 (81.00)
158 (80.20)

1039 (27.88)
378 (23.76)
547 (23.05)
393 (19.00)
44 (19.80)

37.95

<.0001

2111 (72.97)
2786 (78.25)

1303 (27.03)
1118 (421.75)

20.64

<.0001

2026 (76.53)
2780 (75.99)

1106 (23.47)
1185 (24.01)

.13

.7202

3468 (78.25)
1306 (69.38)

1509 (21.74)
807 (30.62)

42.62

<.0001

2374 (77.65)
1718 (73.36)
930 (72.37)

1080 (22.35)
1028 (26.64)
459 (27.63)

13.57

.0011

981 (73.23)
2041 (72.58)
1734 (82.29)

546 (26.77)
1065 (27.43)
563 (17.41)

49.80

<.0001

1896 (79.76)
2150 (76.37)
854 (62.93)

782 (20.24)
1022 (23.63)
667 (37.07)

64.75

<.0001

3404 (75.66)
1580 (73.26)

1697 (24.34)
842 (26.74)

2.79

.0950

602 (14.22)
593 (9.90)
595 (9.00)

550 (24.02)
772 (28.32)
510 (17.56)

51.57
428. 67
76.53

<.0001
<.0001
<.0001

108.60 (20.58)
108.00

58.45 (34.42)
66.00

79.202

<.0001

2

Rao-Scott Chi-square used to correct for weighted frequencies except for age as a continuous variable, where t-test is used.
BMI I<18.5 not included in analyses
4
Body Mass Index stratified by waist circumference (BMI-W),
5
High waist circumference >= 102 cm for men, >= 88 cm for women
6
High waist-to-hip ratio >= 1.0 for men, >=0.9 for women
7
SE= Standard Error of the Mean
3

Table 5- Participant Characteristics and Cause-Specific Mortality

46

Sex
Male
Female

2238 (73.13)1*
2790 (76.53)

46 (0.64)1*
22 (0.53)

77 (1.39)1*
45 (0.98)

1254 (24.84)1*
1121 (21.96)

2649 (74.40)
1076 (69.26)
1077 (81.31)
226 (89.06)

37 (0.55)
20 (1.14)
11 (0.76)
0 (0.00)

78 (1.18)
33 (1.66)
9 (0.46)
2 (0.50)

1504 (23.87)
491 (27.93)
342 (17.48)
38 (10.44)

64.49 (9.40)

73.06 (9.10)

74.42 (10.00)

75.23 (9.77)

873 (93.45)
794 (88.34)
1013 (84.93)
833 (75.13)
743 (69.59)
363 (51.74)
409 (29.72)

2 (0.06)
5 (0.35)
3 (0.16)
15 (0.92)
13 (0.91)
8 (0.89)
22 (1.32)

3 (0.14)
8 (0.84)
14 (0.99)
16 (1.51)
16 (1.29)
18 (1.67)
47 (2.71)

73 (6.34)
111 (10.46)
199 (13.92)
273 (22.44)
353 (28.22)
352 (45.70)
1014 (66.25)

1503 (72.18)
1967 (76.08)
482 (80.17)

27 (0.78)
26 (0.46)
13 (0.52)

46 (1.23)
50 (1.38)
23 (0.84)

900 (25.81)
874 (22.07)
23 (18.47)

1503 (72.18)
768 (76.27)
1202 (76.95)
1254 (81.01)
158 (80.20)

27 (0.78)
15 (0.61)
11 (0.36)
11 (0.57)
2 (0.39)

46 (1.23)
27 (2.09)
22 (0.85)
19 (0.86)
3 (0.97)

900 (25.81)
336 (21.02)
514 (21.84)
363 (17.57)
39 (18.44)

2115 (73.03)
2788 (78.26)

38 (0.61)
28 (0.53)

69 (1.52)
51 (0.88)

Waist-to-hip Ratio6
Normal
High

2031 (76.59)
2781 (75.99)

32 (0.64)
30 (0.45)

C-reactive Protein (mg/dL)
Normal
High

3470 (78.27)
1308 (69.38)

Smoking Status
Never
Past
Current

Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Mexican American
Other
Age
Mean (SD)
Age Group
50-54
55-59
60-64
65-69
70-74
75-79
80+
Body Mass Index3
Normal
Overweight
Obese
BMI-W4
1- Normal
2- Elevated
3- High
4- Very High
5- Extremely High
Waist Circumference5
Normal
High

8.27

.0408

§

§

§

§

935.52

<.0001

31.96

<.0001

48.79

<.0001

1194 (24.84
1039 (20.34

23.37

<.0001

61 (1.32)
54 (1.06)

1011 (21.46)
1101 (22.51)

2.10

.5523

38 (0.41)
24 (0.97)

67 (1.03
40 (1.26)

1402 (20.28)
743 (28.38)

47.01

<.0001

2378 (77.68)
1720 (73.40)
930 (72.37)

29 (0.49)
28 (0.74)
11 (0.44)

58 (1.29)
45 (0.83)
19 (1.56)

991 (20.55)
955 (25.02)
429 (25.63)

23.90

.0005

Alcohol Use
Never
Past
Current

981 (73.23)
2043 (72.60)
1736 (82.60)

14 (0.62)
30 (0.67)
22 (0.54)

24 (0.94)
47 (1.11)
26 (0.94)

508 (25.21)
987 (25.63)
514 (15.92)

71.13

<.0001

Physical Activity Level
More active than others
Less active than others
About the same as others

1897 (79.78)
856 (32.98)
2153 (76.40)

21 (0.43)
9 (0.35)
33 (0.73)

42 (0.98)
30 (1.55)
48 (1.24)

718 (18.82)
628 (35.12)
940 (21.63)

97.43

<.0001

Current NSAID use
Yes
No

3407 (75.68)
1583 (73.29)

49 (0.60)
19 (0.54)

83 (1.08)
39 (1.42)

1564 (22.64)
783 (24.76)

4.43

<.0001

45 (41.05)
24 (12.44)
17 (11.70)

479 (22.91)
734 (29.38)
482 (18.01)

83.79
300.87
102.23

<.0001
<.0001
<.0001

55.42 (4.02)
52.00

61.07 (1.57)
57.00

§

§

Positive Personal History
25 (33.60)
603 (14.22)
Cancer
14 (18.62)
596 (9.96)
Cardiovascular Disease
11 (11.66)
596 (9.02)
Diabetes
Follow-up time in Months
108.43 (1.47)
58.31 (4.65)
Mean (SE)7
Median
108.00
57.00
1
n (%); weighted and rounded percentages.
2
Rao-Scott Chi-Square Test for weighted sample data
3
BMI I<18.5 not included in analyses
4
Body Mass Index stratified by waist circumference (BMI-W),
5
High waist circumference >= 102 cm for men, >= 88 cm for women
6
High waist-to-hip ratio >= 1.0 for men, >=0.9 for women
7
SE= Standard Error of the Mean
§ values can not be obtained due to empty cells
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Table 6 Crude, Age-adjusted, and Multivariate-adjusted Odds Ratios for Mortality in relation to C-reactive Protein Level

A

B

n

Crude Odds Ratio
(95% CI)

Age-adjusted OR
(95% CI)

Multivariate-adjusted OR1
(95% CI)

C-Reactive Protein
Normal
High

4977
2115

1.0
1.589 (1.388-1.819)

1.0
1.628 (1.388-1.909)

1.0
1.318 (1.080-1.610)

C-Reactive Protein
Alive w/normal CRP2
CRC3
Other ORC4
All Other Causes

3470
24
40
743

--2.660 (1.277-5.539)
1.378 (0.798-2.380)
1.579 (1.373-1.816)

--2.723 (1.297-5.719)
1.403 (0.810-2.430)
1.619 (1.375-1.906)

--2.437 (1.203-4.938)
1.212 (0.626-2.344)
1.304 (1.059-1.607)

1

Adjusted for age, sex, race/ethnicity, tobacco use alcohol use, physical activity level, NSAID use, personal history of cancer, personal history of CVD, personal history of diabetes
Referent group: Participants with normal CRP levels who were alive at the end of the study
3
CRC= Colorectal Cancer
4
oORC= Other Obesity-Related Cancer (i.e., breast, endometrial, pancreatic, prostate)
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Table 7 Addition of Adiposity Measures into Multivariate Models estimating Odds Ratios for All-Cause Mortality and
Cause-Specific Mortality in relation to C-Reactive Protein

n

BMI-adjusted OR1,2
(95%CI)

n

BMI-W adjusted OR1,2
(95%CI)

n

C-Reactive Protein
Normal
High

6201

1.0
1.407 (1.140-1.736)

6099

1.0
1.438 (1.175-1.759)

6146

C-Reactive Protein
Alive w/ Normal CRP3
CRC4
o-ORC5
All Other Causes

6201

--2.462 (1.191-5.088)
1.174 (0.610-2.260)
1.392 (1.123-1.725)

6099

--2.765 (1.295-5.904)
1.261 (0.645-2.463)
1.418 (1.155-1.741)

6146

WC-adjusted OR1,2
(95%CI)

1.0
1.375 (1.127-1.678)

--2.849 (1.313-6.183)
1.295 (0.672-2.494)
1.349 (1.099-1.656)

1

n

6011

6011

WHR-adjusted OR1,2
(95%CI)

1.0
1.325 (1.073-1.636)

--2.867 (1.317-6.243)
1.214 (0.621-2.372)
1.302 (1.047-1.618)

Adjusted for age, sex, race/ethnicity, tobacco use alcohol use, physical activity level, NSAID use, personal history of cancer, personal history of CVD, personal history of diabetes.
Body Mass Index (BMI), Body Mass Index stratified by waist circumference (BMI-W), Waist Circumference (WC), Waist-Hip-Ratio (WHR)
3
Referent group: Participants with normal CRP levels who were alive at the end of the study
4
CRC= Colorectal Cancer
5
o-ORC= Other Obesity-related Cancer (i.e., breast, endometrial, pancreatic, prostate)
2
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Table 8 Odds Ratios for All-Cause Mortality in relation to Adiposity
n
BMI
Normal
Overweight
Obese

6200

BMI-W2
Normal
Elevated
High
Very High
Extremely High

6098

Waist Circumference
Normal
High

6145

Waist-to-hip Ratio
Normal
High

6010

1

2

Crude OR
(95% CI)

Age-adjusted OR
(95% CI)

Adjusted OR1
(95% CI)

1.0
0.814 (0.692-0.957)
0.640 (0.539-0.759)

1.0
0.913 (0.754-1.105)
0.910 (0.760-1.089)

1.0
0.791 (0.627-0.997)
0.650 (0.521-0.811)

1.0
0.806 (0.649-1.002)
0.775 (0.651-0.922)
0.607 (0.511-0.721)
0.639 (0.407-1.003)

1.0
0.989 (0.772-1.266)
0.838 (0.688-1.021)
0.859 (0.713-1.036)
1.130 (0.680-1.878)

1.0
0.784 (0.564-1.092)
0.759 (0.598-0.963)
0.633 (0.505-0.792)
0.634 (0.314-1.283)

1.0
1.031 (0.874-1.216)

1.0
0.986 (0.817-1.189)

1.0
0.806 (0.688-0.944)

1.0
1.589 (1.388-1.819)

1.0
1.628 (1.388-1.909)

1.0
1.008 (.814-1.249)

Adjusted for age, sex, race/ethnicity, tobacco use alcohol use, physical activity level, NSAID use, personal history of cancer, personal history of CVD,
personal history of diabetes, and CRP level.
Body Mass Index stratified by waist circumference (BMI-W)
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Table 9 Odds Ratios for Cause-Specific Mortality in relation to Adiposity
Crude Odds
Ratio (95% CI)

Age-adjusted
OR (95% CI)

Multivariate
OR1
(95% CI)

--0.556 (0.275-1.123)
1.066 (.639-1.778)
0.811 (0.684-0.963)

--0.617 (0.299-1.275)
1.170 (.692-1.980)
0.912 (0.747-1.113)

--0.427 (0.208-0.889)
1.024 (.548-1.912)
0.798 (0.639-0.996)

--0.600 (0.271-1.327)
0.612 (0.295-1.270)
0.644 (0.542-0.766)

--0.828 (0.357-1.921)
0.816 (0.392-1.699)
0.922 (0.468-1.106)

--0.663 (0.259-1.696)
0.756 (0.345-1.654)
0.781 (0.631-0.968)

--0.807 (0.407-1.602)
0.538 (0.324-0.896)
0.764 (0.677-0.862)

--0.871 (0.428-1.774)
0.577 (0.346-0.960)
0.838 (0.731-0.961)

--0.810 (0.329-1.996)
0.684 (0.375-1.246)
0.883 (0.760-1.025)

BMI-W5 Elevated
Alive and Normal BMI-W2
CRC
o-ORC
All Other Causes

--0.740 (0.329-1.666)
1.606 (0.874-2.954)
0.771 (0.611-0.972)

--0.894 (0.388-2.059)
1.920 (1.029-3.589)
0.942 (0.725-1.224)

--0.500 (0.244-1.026)
1.381 (0.563-3.386)
0.728 (0.521-1.019)

BMI-W High
Alive with Normal BMI-W2
CRC
o-ORC
All Other Causes

--0.435 (0.185-1.020)
0.648 (0.341-1.230)
0.794 (0.663-0.950)

--0.467 (0.195-1.122)
0.691 (0.361-1.325)
0.862 (0.703-1.056)

--0.397 (0.158-1.002)
0.740 (0.379-1.446)
0.792 (0.633-0.991)

BMI-W Very High
Alive with Normal BMI-W2
CRC
o-ORC
All Other Causes

--0.647 (0.284-1.475)
0.621 (0.302-1.277)
0.607 (0.509-0.723)

--0.893 (0.371-2.146)
1.144 (0.680-1.926)
1.156 (0.163-8.202)

BMI-W Extremely High
Alive with Normal BMI-W2
CRC
o-ORC
All Other Causes

--0.452 (0.087-2.352)
0.710 (0.105-4.776)
0.643 (0.404-1.024)

---0.766 (0.138-4.236)
1.156 (1.101-1.125)
1.144 (0.680-1.926)

--0.711 (0.351-1.438)
0.809 (0.515-1.272)
1.057 (0.893-1.252)

--0.680 (0.330-1.402)
0.770 (0.490-1.209)
1.016 (0.838-1.231)

n
Body Mass Index: Overweight
Alive with Normal BMI2
CRC3
o-ORC4
All Other Causes
7355
Body Mass Index: Obese
Alive and Normal BMI2
CRC
o-ORC
All Other Causes
Waist Circumference
Alive with Normal WC2
CRC
o-ORC
All Other Causes

7322

7220

Waist-to-Hip Ratio
Alive with Normal WHR2
CRC
o-ORC
All Other Causes
1
2
3
4
5

7101

--0.672 (0.261-1.730)
0.797 (0.362-1.757)
0.751 (0.604-0.933)

--0.810 (0.111-5.890)
0.145 (0.028-0.743)
0.895 (0.445-1.798)

--0.547 (0.258-1.158)
0.929 (0.523-1.650)
1.054 (0.860-1.291)

Adjusted for age, sex, race/ethnicity, tobacco use alcohol use, physical activity level, NSAID use, personal history of
cancer, personal history of CVD, personal history of diabetes, and CRP level.
Referent group
CRC= Colorectal Cancer
o-ORC= Other Obesity-related Cancer (i.e., breast, endometrial, pancreatic, prostate)
Body Mass Index stratified by waist circumference (BMI-W)
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